Ayala Pharmaceuticals Inc (fka ADXS)

[gajj]

If EMA approval (along with an EU licensing deal) is imminent than there is no concern whatsoever about a new stock issue save as a component of a deal. These evNnts are likely to occur this year and Advaxis has funds on hand to last through 2018. So, as Alfred E Newman famously observed, "What, me worry?" An expectation of $50/sh by the end of 2017 could be a likelihood.